Amyloidosis trials in Portugal

In Portugal 14 Also abroad 184

14 trials · From ClinicalTrials.gov, checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)
Where
Lisbon
Age
18 years to 90 years
People
1,200 worldwide
Run by
Intellia Therapeutics
See details and how to joinNCT06128629 · EU 2023-507220-23-00
Phase 3Enrolling by invitation
A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy
Where
Creixomil, Lisbon, Porto, Viseu
Age
18 years and over
People
700 worldwide
Run by
Alnylam Pharmaceuticals
See details and how to joinNCT06679946
Phase 3Taking people
TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy
Where
Carnaxide, Guimaraes, Leiria, Lisbon, Vila Real, Viseu
Age
18 years to 85 years
People
1,750 worldwide
Run by
Alnylam Pharmaceuticals
See details and how to joinNCT07052903 · EU 2024-519917-72-00
No phaseTaking people
ConTTRibute: A Global Observational Study of Patients With Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis)
Where
Lisbon, Porto
People
1,500 worldwide
Run by
Alnylam Pharmaceuticals
See details and how to joinNCT04561518
No phaseTaking people
Patisiran-Lipid Nanoparticle (LNP) Pregnancy Surveillance Program
Where
Lisbon
People
10 worldwide
Run by
Alnylam Pharmaceuticals
See details and how to joinNCT05040373
Phase 3Taking people
TRITON-PN: A Study to Evaluate the Efficacy and Safety of Nucresiran in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy
Where
Lisboa, Porto
Age
18 years to 85 years
People
125 worldwide
Run by
Alnylam Pharmaceuticals
See details and how to joinNCT07223203 · EU 2025-522544-40-00
No phaseTaking people
A Study to Learn About the Use of Acoramidis in Patients With a Heart Condition Called Transthyretin Amyloid Cardiomyopathy (ATTR-CM) in a Real-world Setting
Where
Multiple Locations
Age
18 years and over
People
2,000 worldwide
Run by
Bayer
See details and how to joinNCT07235462
No phaseTaking people
OverTTuRe: Characteristics, Treatment Patterns and Outcomes of Patients With ATTR Amyloidosis
Where
Lisbon, Porto
People
52,121 worldwide
Run by
AstraZeneca
See details and how to joinNCT06355934
No phaseTaking people
Retinal Fundus Imaging and OCT Imaging for Ocular Detection of ATTR-CM
Where
Guimarães, Lisbon
Age
18 years and over
People
500 worldwide
Run by
AstraZeneca
See details and how to joinNCT07690436
Phase 3Not yet taking people in Portugal
To Evaluate the Long-term Safety and Tolerability of Acoramidis in Participants With Newly Diagnosed ATTR-CM (ACT-EARLY OLE)
Where
Lisbon, Porto
Age
18 years and over
People
250 worldwide
Run by
Eidos Therapeutics, a BridgeBio company
See details and how to joinNCT07116473 · EU 2024-513676-18-00
Phase 3Taking people
Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant
Where
Lisbon, Porto
Age
18 years to 75 years
People
587 worldwide
Run by
Eidos Therapeutics, a BridgeBio company
See details and how to joinNCT06563895 · EU 2024-513547-82-00
Phase 3Enrolling by invitation
An Extension Study to Assess Long-Term Safety of Eplontersen in Adults With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)
Where
Guimarães, Lisbon, Porto
Age
18 years and over
People
1,400 worldwide
Run by
Ionis Pharmaceuticals, Inc.
See details and how to joinNCT05667493
No phaseTaking people
Exercise in Hereditary ATTR (ATTRv) Amyloidosis
Where
Maia
Age
18 years and over
People
42
Run by
University of Maia
See details and how to joinNCT07033715
No phaseTaking people
International Cardiac Amyloidosis Registry
Where
Lisbon
Age
18 years and over
People
300 worldwide
Run by
Leiden University Medical Center
See details and how to joinNCT06894290